ReShape Lifesciences (RSLS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update Entered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Significant Reduction in Overall Operating Expenses of 45.4% in the First Half of 2024 Compared to the First Half of 2023 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 IRVINE, Calif., August 14, 2024 -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier ph ...